Ovid Therapeutics (OVID) Price & Analysis

Compare

1,513 Followers

OVID Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.24 - $1.47

Previous CloseN/A

Volume22.63K

Average Volume (3M)1.64M

Market Cap

$91.02M

Enterprise Value-$788.97K

Total Cash (Recent Filing)$38.35M

Total Debt (Recent Filing)$1.38M

Price to Earnings (P/E)―

Beta2.21

Next Earnings

Nov 12, 2025

EPS Estimate

-0.14

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.06

Shares Outstanding71,109,510

10 Day Avg. Volume1,253,066

30 Day Avg. Volume1,644,400

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap>-0.01

Enterprise Value/Revenue-0.12

Enterprise Value/Gross Profit-0.12

Enterprise Value/Ebitda0.02

Forecast

1Y Price Target

$3.40

Price Target Upside198.25% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Clinical TrialsSuccessful completion of Phase 1 trials will enable OVID to progress to Phase 2 trials, potentially increasing the value of their drug portfolio.

EarningsOVID shares trading at approximately $50M present an attractive risk/reward opportunity with potential for an upward re-rating should the Phase 1 data provide target validation.

Financial PerformanceRoyalty monetization deal with Immedica Pharma AB strengthens Ovid's balance sheet by selling ganaxolone royalty rights for $7.0 million.

Bears Say

Company NeedsThe company needs cash.

Development ActivitiesResearch and development expenses have seen a slight decrease, which might indicate a slowdown in certain development activities.

Ovid Therapeutics News

Ovid Therapeutics Regains Nasdaq Compliance

Ovid Therapeutics ( ($OVID) ) has shared an update. On September 11, 2025, Ovid Therapeutics Inc. announced that...

2d ago

OVID

Ovid Therapeutics’ Promising Pipeline and Strategic Developments Justify Buy Rating

Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Ovid Therapeutics. The associated price target...

24d ago

OVID

3 Best Stocks to Buy Now, 8/18/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

1M ago

BZAI

OVID

Ovid Therapeutics: Promising Pipeline and Strong Financial Health Justify Buy Rating

TD Cowen analyst Ritu Baral has maintained their bullish stance on OVID stock, giving a Buy rating on...

1M ago

OVID

Ovid Therapeutics Navigates FDA Disruptions and Government Challenges

Ovid Therapeutics (OVID) has disclosed a new risk, in the Taxation & Government Incentives category. Ovid Therapeutics faces...

1M ago

OVID

Ovid Therapeutics Reports Increased Revenue Amid Challenges

Ovid Therapeutics ( ($OVID) ) has released its Q2 earnings. Here is a breakdown of the information Ovid...

1M ago

OVID

Ovid Therapeutics: Strategic Advances and Promising Developments Justify Buy Rating

William Blair analyst Myles Minter has maintained their bullish stance on OVID stock, giving a Buy rating today....

1M ago

OVID

Ovid Therapeutics Transfers Stock to Nasdaq Capital Market

Ovid Therapeutics ( ($OVID) ) has provided an update. Ovid Therapeutics received approval to transfer its common stock...

1M ago

OVID

Ovid Therapeutics reports Q2 EPS (6c), consensus (15c)

Reports Q2 revenue $6.3M, consensus $91,800″Our pipeline continues to advance across multiple fronts, with several key readouts anticipated...

1M ago

OVID

Ovid Therapeutics sees cash runway into 2H26

Ovid expects its cash runway to support operations and clinical development programs into early second half 2026, during...

1M ago

OVID

Ovid Therapeutics initiated with a Buy at Lucid Capital

Lucid Capital initiated coverage of Ovid Therapeutics (OVID) with a Buy rating and $5.50 price target The firm...

1M ago

OVID

Ovid Therapeutics transferred with Buy rating at B. Riley

B. Riley keeps a Buy rating on Ovid Therapeutics (OVID) with a $3 price target following a transfer...

1M ago

OVID

Ovid Therapeutics management to meet with B. Riley

Meeting to be held in New York on July 22 hosted by B. Riley. Published first on TheFly...

2M ago

OVID

Ovid Therapeutics Approves Key Proposals at Annual Meeting

Ovid Therapeutics ( ($OVID) ) has provided an update. On July 9, 2025, Ovid Therapeutics held its annual...

2M ago

OVID

OVID FAQ

What was Ovid Therapeutics Inc’s price range in the past 12 months?

Ovid Therapeutics Inc lowest stock price was $0.24 and its highest was $1.47 in the past 12 months.

What is Ovid Therapeutics Inc’s market cap?

Ovid Therapeutics Inc’s market cap is $91.02M.

When is Ovid Therapeutics Inc’s upcoming earnings report date?

Ovid Therapeutics Inc’s upcoming earnings report date is Nov 12, 2025 which is in 55 days.

How were Ovid Therapeutics Inc’s earnings last quarter?

Ovid Therapeutics Inc released its earnings results on Aug 13, 2025. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.158 by $0.098.

Is Ovid Therapeutics Inc overvalued?

According to Wall Street analysts Ovid Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Ovid Therapeutics Inc pay dividends?

Ovid Therapeutics Inc does not currently pay dividends.

What is Ovid Therapeutics Inc’s EPS estimate?

Ovid Therapeutics Inc’s EPS estimate is -0.14.

How many shares outstanding does Ovid Therapeutics Inc have?

Ovid Therapeutics Inc has 71,109,510 shares outstanding.

What happened to Ovid Therapeutics Inc’s price movement after its last earnings report?

Ovid Therapeutics Inc reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.158. Following the earnings report the stock price went up 56.364%.

Which hedge fund is a major shareholder of Ovid Therapeutics Inc?

Currently, no hedge funds are holding shares in OVID

Ovid Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-52.77%

Trailing 12-Months

Asset Growth

-34.43%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Ovid Therapeutics Inc

Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with rare neurological disorders. The company is dedicated to addressing significant unmet medical needs in conditions such as epilepsy, fragile X syndrome, and other neurodevelopmental disorders by leveraging its deep expertise in neuroscience and drug development. Ovid's core products include its pipeline of drug candidates, with a focus on developing treatments that can improve patient outcomes and quality of life.

Ovid Therapeutics (OVID) Earnings & Revenues

Historic Earnings Reports

OVID Stock 12 Month Forecast

Average Price Target

$3.40

▲(198.25% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","-1":"-$1","0.75":"$0.75","2.5":"$2.5","4.25":"$4.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$5.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.75,2.5,4.25,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.5,0.8846153846153846,1.2692307692307692,1.653846153846154,2.0384615384615383,2.4230769230769234,2.807692307692308,3.1923076923076925,3.576923076923077,3.9615384615384617,4.346153846153847,4.730769230769231,5.115384615384616,{"y":5.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.5,0.7230769230769231,0.9461538461538461,1.169230769230769,1.3923076923076922,1.6153846153846154,1.8384615384615384,2.0615384615384613,2.2846153846153845,2.5076923076923077,2.730769230769231,2.9538461538461536,3.1769230769230767,{"y":3.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.5,0.5769230769230769,0.6538461538461539,0.7307692307692308,0.8076923076923077,0.8846153846153846,0.9615384615384616,1.0384615384615385,1.1153846153846154,1.1923076923076923,1.2692307692307692,1.3461538461538463,1.4230769230769231,{"y":1.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.86,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.99,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.13,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.12,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.14,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.14,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.93,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.53,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.31,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.32,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.32,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >